Group 1 - The company is actively promoting its "Tongjun Traditional Chinese Medicine Culture" as part of its efforts to protect and inherit national intangible cultural heritage and enhance the brand power of "Chinese Time-honored Brand" [1] - The company is expanding its product offerings in the "Chinese Medicine +" and "Food and Medicine Homology" markets, leveraging its full subsidiary Tongjun Tang Pharmaceutical Co., Ltd. [1] - The company has introduced high-quality traditional Chinese medicine products such as wild ginseng and Dendrobium slices, along with health products like Ejiao cake and broken-wall Ganoderma lucidum spore powder, while also preparing for market demands in food and medicine homology products [1] Group 2 - An investor inquired about the company's strategy regarding the market for nourishing products, such as ginseng and goji berries, suggesting that the company could capture this market based on the logic of food and medicine homology [3]

Group 1 - The Chinese medicine ETF (159647) has seen a continuous inflow of funds, totaling 30.03 million yuan over the past five days, with a net inflow of 22.14 million yuan since August [1] - The China Traditional Chinese Medicine Index (930641) has increased by 0.77%, with notable gains from companies such as Kang En Bei (600572) up 5.41% and Zhong Sheng Pharmaceutical (002317) up 4.80% [1] - The release of the "Chinese Atrial Fibrillation Management Guidelines (2025)" recommends the use of Tongluo drugs, specifically the Shen Song Yang Xin capsule, for maintaining sinus rhythm in paroxysmal atrial fibrillation [1] Group 2 - Jiang Hai Securities highlights that the labeling of expiration dates on traditional Chinese medicine pieces enhances product transparency, boosting consumer confidence and potentially expanding the market [2] - The top ten weighted stocks in the China Traditional Chinese Medicine Index account for 54.58% of the index, with major companies including Yunnan Baiyao (000538) and Tong Ren Tang (600085) [2] - The Chinese medicine ETF closely tracks the China Traditional Chinese Medicine Index, which reflects the overall performance of listed companies involved in the production and sale of traditional Chinese medicine [2]

太龙药业最新一期业绩显示，截至2025一季报，公司营业总收入3.23亿元、同比减少35.23%，归属净利 润153.06万元，同比减少92.80%，扣非净利润45.79万元，同比减少97.59%，流动比率1.128、速动比率 0.922、资产负债率54.26%。 金融界消息 截至2025年8月11日收盘，太龙药业（600222）报收于6.75元，上涨2.12%，换手率 11.43%，成交量65.57万手，成交金额4.41亿元。 天眼查商业履历信息显示，河南太龙药业股份有限公司，成立于1998年，位于郑州市，是一家以从事医 药制造业为主的企业。企业注册资本57388.6283万人民币，实缴资本10114.524万人民币。公司法定代表 人为尹辉。 资金流向方面，今日主力资金净流出2252.57万元，占比成交额5.11%。其中，超大单净流出688.43万 元、占成交额1.56%，大单净流出1564.14万元、占成交额3.55%，中单净流出流出1159.78万元、占成交 额2.63%，小单净流入3412.34万元、占成交额7.74%。 通过天眼查大数据分析，河南太龙药业股份有限公司共对外投资了14家企业，参与招投标项 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-039 河南太龙药业股份有限公司 关于公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）近日收到河南 省药品监督管理局核准签发的《药品生产许可证》，现将相关情况公 告如下： 一、签发后的《药品生产许可证》相关情况 企业名称：河南太龙药业股份有限公司 许可证编号：豫 20150080 分类码：AhztBzChDh 注册地址：郑州高新技术产业开发区金梭路 8 号 发证机关：河南省药品监督管理局 有效期至：2025 年 12 月 31 日 生产地址和生产范围： 河南省巩义市竹林镇：原料药，精神药品，片剂，颗粒剂，硬胶 囊剂(含中药前处理及提取) 郑州高新技术产业开发区金梭路 8 号：露剂、糖浆剂、合剂(含 口服液、中药前处理及提取) 二、《药品生产许可证》所涉药品情况 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-039 Z36021319)由委托浙江国光生物制药有限公 ...

河南太龙药业股份有限公司 关于公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）近日收到河南 省药品监督管理局核准签发的《药品生产许可证》，现将相关情况公 告如下： 一、签发后的《药品生产许可证》相关情况 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-039 郑州高新技术产业开发区金梭路 8 号：露剂、糖浆剂、合剂(含 口服液、中药前处理及提取) 二、《药品生产许可证》所涉药品情况 1、公司金银花露(国药准字 Z36021325)、板蓝根糖浆(国药准字 企业名称：河南太龙药业股份有限公司 许可证编号：豫 20150080 分类码：AhztBzChDh 注册地址：郑州高新技术产业开发区金梭路 8 号 发证机关：河南省药品监督管理局 有效期至：2025 年 12 月 31 日 生产地址和生产范围： 河南省巩义市竹林镇：原料药，精神药品，片剂，颗粒剂，硬胶 囊剂(含中药前处理及提取) 证券代码：600222 证券简称：太龙药业 公告编号 ...

河南太龙药业股份有限公司 目 录 议案五 关于修订《董事和高级管理人员薪酬管理办法》的议案 . 47 为维护投资者的合法权益，确保本次股东大会顺利进行，河南太 龙药业股份有限公司（以下简称"公司"）根据《中华人民共和国公 司法》《上市公司股东会规则》以及《公司章程》等有关规定，制定 会议须知如下： 一、本次股东大会设秘书处，负责会议组织工作和处理相关事宜。 二、为保证本次股东大会的严肃性和正常秩序，除依法出席会议 的公司股东（或股东代理人）、董事、监事、高级管理人员、聘请的 律师及相关工作人员外，公司有权依法拒绝其他人士入场。 三、出席会议的股东（或股东代理人）必须在会议召开前十分钟 向大会秘书处办理签到、登记手续。 四、股东（或股东代理人）参加股东大会依法享有发言权、质询 权、表决权等权利。股东需要发言或就有关问题进行提问的，应在会 议登记期间向大会秘书处进行登记，大会秘书处将按登记顺序安排股 东发言。股东发言或提问应围绕本次会议议题进行，简明扼要，每位 股东发言时间原则上不超过 5 分钟。在大会进行表决时股东不得发言。 五、大会期间，全体参会人员应遵守会场秩序，不得在会场大声 喧哗、随意走动。会议期间请将 ...

河南太龙药业股份有限公司 2025 年第三次临时股东大会会议资料 2025 年 8 月 目 录 | 2025 | 年第三次临时股东大会会议须知 2 | | --- | --- | | 2025 | 年第三次临时股东大会会议议程 3 | | 议案一 | 关于取消监事会并修订《公司章程》的议案 4 | | 议案二 | 关于修订《股东会议事规则》的议案 44 | | 议案三 | 关于修订《董事会议事规则》的议案 45 | | 议案四 | 关于修订《独立董事工作制度》的议案 46 | | 议案五 | 关于修订《董事和高级管理人员薪酬管理办法》的议案. 47 | | 议案六 | 关于选举第十届董事会非独立董事的议案 48 | | 议案七 | 关于选举第十届董事会独立董事的议案 50 | 1 2025 年第三次临时股东大会会议须知 为维护投资者的合法权益，确保本次股东大会顺利进行，河南太 龙药业股份有限公司（以下简称"公司"）根据《中华人民共和国公 司法》《上市公司股东会规则》以及《公司章程》等有关规定，制定 会议须知如下： 一、本次股东大会设秘书处，负责会议组织工作和处理相关事宜。 二、为保证本次股东大会的严肃性和正常 ...

Group 1 - The stock price of Tailong Pharmaceutical closed at 6.66 yuan on August 4, 2025, down 0.16 yuan or 2.35% from the previous trading day [1] - The opening price was 7.15 yuan, with a highest price of 7.15 yuan and a lowest price of 6.59 yuan, indicating significant intraday volatility [1] - The trading volume was 1,148,600 hands, with a transaction amount of 777 million yuan and a turnover rate of 20.01% [1] Group 2 - Tailong Pharmaceutical operates in the traditional Chinese medicine manufacturing industry, focusing on the research, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company's product range includes cold medicines, cardiovascular drugs, and digestive system medications, covering multiple therapeutic areas [1] Group 3 - On August 4, the company experienced rapid fluctuations in stock price, with a rebound of over 2% within 5 minutes around 9:40 AM, followed by a decline of over 2% within 5 minutes around 9:45 AM [1] - The net outflow of main funds on that day was 79.01 million yuan, accounting for 2.07% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 27.16 million yuan, representing 0.71% of the circulating market value [1]

A股中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]